In response to a comprehensive safety review prompted by a recent European study, the Medicines and Healthcare Products Regulatory Agency (MHRA) is introducing enhanced safety protocols for topiramate, commonly known by its brand name Topamax.
[block_2]
The Commission on Human Medicines (CHM) scrutinised research findings related to topiramate use during pregnancy. These studies revealed that children born to mothers who took topiramate faced a risk level approximately 2 to 3 times higher for intellectual disability, autism spectrum disorders, and attention deficit hyperactivity disorder.
Stay connected to UKNIP via Google News
ENJOYED THIS STORY? Choose UKNIP as a 'Preferred Source' on Google News for quick access to the news you value.
